High drug costs, under-the-radar insurer policies can put patients in a bind as hefty copays mount.
Dec 15, 2022
Premium
Image
An epic tug of war is playing out behind the scenes over whether the government should pay for Aduhelm, a controversial Alzheimer’s drug that scientists say has not been proven to work./Lydia Zuraw/KHN
Pharmaceutical industry and patients representatives want to stop restricting Medicare funding for a controversial Alzheimer’s drug. Critics say it should never have been approved.
The pharmacies can start vaccinating Feb. 11 for those who qualify -- which will include people 80 and over but don't expect any one place to have a big stock.